Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
about
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonistsVitamin B12 deficiency is associated with adverse lipid profile in Europeans and Indians with type 2 diabetes.Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammationGlycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.Incretin-based therapies in prediabetes: Current evidence and future perspectivesSelective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesTreating coronary disease and the impact of endothelial dysfunction.Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-DiabetesChronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony.Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes.Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection.Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans.Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production.Direct cardiovascular effects of glucagon like peptide-1.The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.Do incretins improve endothelial function?Extra-pancreatic effects of incretin-based therapies.Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.GLP-1: benefits beyond pancreas.Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus.Antidiabetic agents and endothelial dysfunction - beyond glucose control.Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.Exenatide: pharmacokinetics, clinical use, and future directions.Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds.Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: An experimental study.Transcriptomic effects of metformin in skeletal muscle arteries of obese insulin-resistant rats.Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case-Control Study.Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy
P2860
Q26823085-BC9F8156-9464-4F40-BC69-2C12488978E8Q34305997-767786E1-B0C0-4272-A941-221ACE1EE85BQ34405101-2018250F-B6EB-4C10-8A8B-5ACA15ADB843Q34486820-39FDA604-7501-4AD8-B865-704C878BAED4Q34560277-5E675E49-6AFD-4E4F-8F2A-908A623B1167Q34699191-439242ED-219B-49F6-B4D6-897E6E32C348Q34994502-0B1C319C-B610-4560-902B-C4312FEE485AQ35196366-83B7CF99-81CD-41B0-844B-957A5C9B622BQ35209811-8BD0B2C0-7983-43AE-ACD7-4E03DBF0B700Q35532329-0E0681ED-728D-44F7-B116-7180D971E4B9Q35748827-79FEC518-D871-4B63-8BFA-D3E394A52CF1Q35784692-619F097F-74A9-46E1-B2F0-2B3031C0266DQ36072493-5597DA0F-1682-4DEA-A0A8-B3710D52FC97Q36402823-0AC02B5B-D73A-4803-948D-E3C373A367CBQ36755470-EF55E55C-880B-452E-BDA5-018532174ABFQ36976130-780C5E1F-3E9B-4856-931B-852283A49243Q36980756-BE717535-1C57-42B7-9557-9F30AC67B3CEQ37153223-210C7C44-6FEA-42DF-9ED7-46B84F50554BQ37402790-60BE3CE9-FD2A-41A4-9442-1282CE1D3968Q37686091-0BE8AF07-7C10-42C2-A30F-6AC493EAD43BQ38132470-7D9492A4-9D0B-46EF-B242-321E0959C42CQ38174279-FB28E5FD-C5FF-4156-AFEE-2CC05E5F5097Q38178761-F390E59E-D30C-4207-BF13-30B53AEBBBA0Q38194069-6CBDDD15-4B40-4156-9118-F977BCC1C3E7Q38199984-480950A9-417B-4343-BE31-933AF87F8D54Q38238288-1AEDEDFE-0BF8-4FE9-9881-79C562D3C355Q38259933-8EAA9F67-F512-401B-9ED8-C49B886A426EQ38397635-992D1BE2-CA27-465D-8905-11AF5C585E72Q38708352-4414566C-152C-4041-87C6-5166A6A9A4BFQ38770746-888EBA80-08BF-49F4-B404-D67F49E92E7AQ38794395-0985E2B2-D32E-4F45-A1A9-1D45C6EDF39BQ39699152-CCC499CB-50F3-44D3-8B56-22E919A5FFEEQ42319765-6B3299CB-106A-4C39-BC41-A774D4A374ACQ46892741-DEA48827-8157-42CB-9B8C-4D726B3D33ECQ50920115-7A5F620D-6605-4DC7-8434-EA429D64E27AQ53683295-1F6370D1-1D3B-4E33-814E-EF20C0F9B453Q58167256-A9A60F96-2610-4C09-9ED5-3261D95F1A48
P2860
Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effects of exenatide vs. metfo ...... -diabetes: a randomized trial.
@ast
Effects of exenatide vs. metfo ...... -diabetes: a randomized trial.
@en
type
label
Effects of exenatide vs. metfo ...... -diabetes: a randomized trial.
@ast
Effects of exenatide vs. metfo ...... -diabetes: a randomized trial.
@en
prefLabel
Effects of exenatide vs. metfo ...... -diabetes: a randomized trial.
@ast
Effects of exenatide vs. metfo ...... -diabetes: a randomized trial.
@en
P2093
P2860
P921
P356
P1476
Effects of exenatide vs. metfo ...... -diabetes: a randomized trial.
@en
P2093
Aaron S Kelly
Alan J Bank
Harold Katz
J Michael Gonzalez-Campoy
Richard M Bergenstal
P2860
P2888
P356
10.1186/1475-2840-11-64
P407
P577
2012-06-08T00:00:00Z
P5875
P6179
1012070743